WHO SUPPORT US

Industrial funding

2022-present
Development of a drug candidate for the therapy of dementia associated with ageing, Alzheimer's disease, depression and multiple sclerosis
R-Pharm — Ministry of Science and Higher Education of the Russian Federation, Russia

2019-present
Design and synthesis of a new generation of direct-acting anti-influenza drugs
OTCPharm, Russia

Public funding

2024-2026
Fundamental principles for the development of small-molecule blockers of virus-host cell interactions
Russian Science Foundation (RSF), Russia

2021-2023
Bringing mycobacterial secretion inhibitors to maturation
Netherlands Antibiotic Development Platform (NADP), Netherlands

2021-2023
Virulence factors of Mycobacterium tuberculosis as a new target for small molecules with the prospect of developing drugs with an original mechanism of action
Russian Science Foundation (RSF), Russia

2021-2022
Drug candidate PDSTP for use in the prevention and treatment of viral infections caused by SARS-CoV-2
Ministry of Science and Higher Education of the Russian Federation, Russia

2019-2023
New weapons against Mycobacterium abscessus and other nontuberculous mycobacteria
Italian Cystic Fibrosis Research Foundation (FCC), Italy

2021-2022
Multidisciplinary platform based on artificial intelligence for accelerating drug discovery and repurposing for COVID-19
Russian Foundation for Basic Research (RFBR), Russia

2017-2019
New generation of non-nucleoside reverse transcriptase HIV inhibitors avoiding HIV-associated neurocognitive disorders
RFBR — National Institute of Allergy and Infectious Diseases, Russia-USA

2017-2019
Thienopyrimidines highly active against Mycobacterium tuberculosis: target identification and mechanism-of-action study
RFBR, Russia

2016-2018
Design, synthesis and mode-of-action study of new original heterocyclic compounds with activity on latent tuberculosis infection
Ministry of Science and Higher Education of the Russian Federation, Russia

2016-2018
New inhalable compounds against the CF pathogen Burkholderia cenocepacia
Cystic Fibrosis Foundation, USA

2013-2020
Pre-clinical studies on a heparan receptor-blocking compound for the treatment of herpesvirus infections, including their generalized forms
Pharma-2020 Strategy, Ministry of Industry and Trade of the Russian Federation, Russia

2011-2016
More Medicines for Tuberculosis (MM4TB)
The 7th Research Framework Programme, European Commission, EU

2006-2010
New Medicines for Tuberculosis (NM4TB)
The 6th Research Framework Programme, European Commission, EU